Ingrid Delaet Sells 273 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 273 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the completion of the transaction, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,055,108.85. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ingrid Delaet also recently made the following trade(s):

• On Thursday, March 21st, Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00.
• On Monday, March 11th, Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $140.00, for a total transaction of $28,000.00.
• On Friday, March 8th, Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $140.03, for a total transaction of $252,054.00.
• On Thursday, February 29th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.51, for a total transaction of $36,994.23.

Neurocrine Biosciences Trading Down 2.9 %

NBIX stock traded down $4.17 during midday trading on Wednesday, hitting $139.02. The stock had a trading volume of 653,593 shares, compared to its average volume of 845,459. The firm has a market capitalization of $13.99 billion, a price-to-earnings ratio of 38.63 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37. The stock has a 50-day simple moving average of $137.63 and a 200 day simple moving average of $129.45.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Neurocrine Biosciences’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the business earned $0.88 earnings per share. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current year.

Analyst Ratings Changes

NBIX has been the subject of a number of research analyst reports. HC Wainwright upped their price target on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Guggenheim upped their price target on shares of Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. The Goldman Sachs Group upped their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Barclays upped their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average target price of $147.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NBIX. Motley Fool Asset Management LLC increased its stake in shares of Neurocrine Biosciences by 337.9% in the first quarter. Motley Fool Asset Management LLC now owns 8,188 shares of the company’s stock valued at $1,129,000 after buying an additional 6,318 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Neurocrine Biosciences by 3.3% in the first quarter. ProShare Advisors LLC now owns 11,829 shares of the company’s stock valued at $1,631,000 after buying an additional 383 shares in the last quarter. QRG Capital Management Inc. increased its stake in shares of Neurocrine Biosciences by 9.3% in the first quarter. QRG Capital Management Inc. now owns 15,878 shares of the company’s stock valued at $2,190,000 after buying an additional 1,352 shares in the last quarter. Inspire Investing LLC increased its position in Neurocrine Biosciences by 96.7% in the first quarter. Inspire Investing LLC now owns 12,296 shares of the company’s stock worth $1,696,000 after purchasing an additional 6,045 shares during the period. Finally, Donoghue Forlines LLC increased its position in Neurocrine Biosciences by 19.6% in the first quarter. Donoghue Forlines LLC now owns 1,851 shares of the company’s stock worth $255,000 after purchasing an additional 303 shares during the period. 92.59% of the stock is owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.